1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21231, USA.
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2829-34. doi: 10.1158/1055-9965.EPI-09-0557. Epub 2009 Oct 20.
Most inherited cancer syndromes are characterized by the familial clustering of cancers at several organ sites. To determine if cancers, other than pancreatic cancer, cluster in pancreatic cancer kindreds, we examined mortality patterns among the relatives of National Familial Pancreatic Tumor Registry probands. Over 200,000 person-years of follow-up from 8,564 first-degree relatives of probands and 1,007 spouse controls were included in these analyses. We compared mortality rates of National Familial Pancreatic Tumor Registry participants to US population rates using weighed standardized mortality ratios (wSMR). Analyses were stratified by family history of pancreatic cancer (sporadic versus familial), family history of young onset pancreatic cancer (<50 years), and family history score. Cancer mortality was increased in both the relatives of sporadic probands [wSMR 1.55, 95% confidence interval (95% CI) 1.39-1.73] and familial probands (wSMR 1.41, 95% CI 1.26-1.58). Relatives of familial probands had a significantly increased risk of dying from breast (wSMR 1.66, 95% CI 1.15-2.34), ovarian (wSMR 2.05, 95% CI 1.10-3.49), and bile duct cancers (wSMR 2.89, 95% CI 1.04-6.39). Relatives of sporadic probands were at increased risk of dying from bile duct cancer (wSMR 3.01, 95% CI 1.09-6.67). Relatives of young onset probands were at higher risk of dying from cancers of the breast (wSMR 1.98, 95% CI 1.01-3.52), colon (wSMR 2.31, 95% CI 1.30-3.81) and prostate (wSMR 2.31, 95% CI 1.14-4.20). Increased cancer mortality was not observed in the spouse controls. Our results show that relatives of pancreatic cancer patients are at higher risk of developing cancers at other sites and highlight the importance of complete family history in clinical risk assessment.
大多数遗传性癌症综合征的特征是在几个器官部位发生癌症的家族聚集。为了确定胰腺癌家族中是否除胰腺癌以外的其他癌症也存在聚集,我们检查了国家家族性胰腺肿瘤登记处患者亲属的死亡率模式。在这些分析中,包括了来自 8564 名一级亲属和 1007 名配偶对照的超过 20 万个人年的随访。我们使用加权标准化死亡率比 (wSMR) 将国家家族性胰腺肿瘤登记处参与者的死亡率与美国人口死亡率进行了比较。分析按胰腺癌家族史(散发性与家族性)、早发性胰腺癌家族史(<50 岁)和家族史评分进行分层。散发性患者的亲属[wSMR 1.55,95%置信区间(95%CI)1.39-1.73]和家族性患者的亲属[wSMR 1.41,95%CI 1.26-1.58]的癌症死亡率均升高。家族性患者亲属死于乳腺癌(wSMR 1.66,95%CI 1.15-2.34)、卵巢癌(wSMR 2.05,95%CI 1.10-3.49)和胆管癌(wSMR 2.89,95%CI 1.04-6.39)的风险显著增加。散发性患者亲属死于胆管癌的风险增加(wSMR 3.01,95%CI 1.09-6.67)。早发性患者亲属死于乳腺癌(wSMR 1.98,95%CI 1.01-3.52)、结肠癌(wSMR 2.31,95%CI 1.30-3.81)和前列腺癌(wSMR 2.31,95%CI 1.14-4.20)的风险更高。配偶对照未观察到癌症死亡率增加。我们的结果表明,胰腺癌患者的亲属发生其他部位癌症的风险更高,这突显了在临床风险评估中全面家族史的重要性。